Trial Condition(s):

Hyperphosphatemia

BAY 77-1931 Long-term Extension from Phase II Study

Bayer Identifier:

11551

ClinicalTrials.gov Identifier:

NCT00769496

EudraCT Number:

Not Available

Study Completed

Trial Purpose

A long-term study of BAY77-1931 (lanthanum carbonate) for hyperphosphatemia in patients undergoing hemodialysis

Inclusion Criteria
- Undergoing hemodialysis 3 times per week for chronic renal failure for the previous 3 consecutive months at least
Exclusion Criteria
- Pre-dialysis serum phosphate levels of 10.0mg/dL during the washout period

Trial Summary

Enrollment Goal
145
Trial Dates
black-arrow
Phase
2
Could I receive a placebo?
No
Products
Fosrenol (Lanthanum Carbonate, BAY77-1931)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Mihama Hospital

Chiba, Japan, 261-0011

Status
Completed
 
Locations

Shin Kashiwa Clinic

Kashiwa, Japan, 277-0084

Status
Completed
 
Locations

Ama Kyoritsu Clinic

Yatomi, Japan, 498-0006

Status
Completed
 
Locations

Kawashima Hospital

Tokushima, Japan, 770-0011

Status
Completed
 
Locations

Shimazu Hospital

Kochi, Japan, 780-0066

Status
Completed
 
Locations

Kochi Takasu Hospital

Kochi, Japan, 781-5103

Status
Completed
 
Locations

Kitasaito Hospital

Asahikawa, Japan, 070-0030

Status
Completed
 
Locations

Inoue Hospital

Suita, Japan, 564-0053

Status
Completed
 
Locations

Mihama Narita Clinic

Narita, Japan, 286-0041

Status
Completed
 
Locations

Mihama Shizu Clinic

Sakura, Japan, 285-0846

Status
Completed
 
Locations

Meiyo Clinic

Toyohashi, Japan, 441-8023

Status
Completed
 
Locations

Shigei Medical Research Hospital

Okayama, Japan, 701-0202

Status
Completed
 
Locations

Nakajima Tsuchiya Clinic

Hiroshima, Japan, 730-0811

Status
Completed
 
Locations

Koseinenkin Kochi Rehabilitation Hospital

Kochi, Japan, 780-8040

Status
Completed
 
Locations

Kawashima Cardiovascular Clinic

Tokushima, Japan, 770-0011

Status
Completed
 

Trial Design